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Is it time to consider 
glaucoma screening 
cost-effective?
Jianjun Tang and colleagues (July, 
2019)1 analysed the cost-effectiveness 
and cost-utility of population-based 
glaucoma screening in urban and rural 
China. Since the cost-utility analysis, 
which was based on Markov models, 
might be sensitive to parametric 
uncertainty, we believe some 
discussion is required.
Data regarding the prevalence of 
transition from one stage of glaucoma 
to another are scarce, especially 
when considering bilateral contexts: 
in clinical studies, data are usually 
presented by eye. We wonder how the 
authors have estimated the prevalence 
of bilateral transition in their study. 
The cited cross-sectional analysis2 
does not provide this information. 
Nevertheless, the authors presented 
estimates with an accuracy of two 
decimal places.
Data on the utility of screening 
for glaucoma are also limited. Tang 
and colleagues only cited one study,3 
which estimated the health utility 
index solely from the visual acuity of 
60 patients, but this previous study 
not did not evaluate patients’ quality 
of life. Assessing utility on the basis of 
visual acuity in patients with glaucoma 
is fairly inaccurate, since patients 
with early and moderate loss of their 
visual field manifest good visual 
function, even in their worse eye. 
Moreover, the applied utility seemed 
relatively low, with assumptions 
of 0·80 for those with mild primary 
open angle glaucoma (POAG), 0·75 
for those with moderate POAG, and 
0·71 for those with severe POAG. 
According to Hagman,4 even in cases 
of severe glaucoma, the utility should 
be considered higher than these 
estimates, reaching 0·82–0·94.
Notably, to date, no screening 
method is sufficient to detect glau-
coma.5 Within the study by Tang 
and colleagues,1 the sensitivity and 
specificity were relatively low; the high 
rate of false-positive and false-negative 
results will lead to additional workload 
for ophthalmologists, which will require 
prioritisation of the available resources. 
In patients who are later found to have 
been given a false-positive diagnosis 
of glaucoma, medications should be 
withdrawn when it is confirmed they 
do not develop manifest glaucoma.5 
We believe that, in the future, 
improved accuracy of automated 
imaging diagnostics (including the 
use of artificial intelligence) and more 
effective treatment options against 
glaucoma progression could attenuate 
health-care resource use, after which 
the cost–benefit ratio would favour 
screening for glaucoma.
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